Coherus Biosciences | CHRS - Interest Expense On Debt


Coherus Biosciences reported $2.25M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 362.52M 357.69M Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 657M 4M Mar/2026
Baxter International USD 58M 14M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fujifilm JPY 863M 429M Mar/2026
Gilead Sciences USD 240M 15M Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Merck USD 479M 67M Mar/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 4.7M 2.65M Mar/2026
Zoetis USD 62M 5M Mar/2026